Schwab Manfred
Division of Cytogenetics, Deutsches Krebsforschungszentrum, Im Neuenheimer Feld 280, D-69120 Heidelberg, Germany.
Ann N Y Acad Sci. 2002 Jun;963:63-73.
Increase in the dosage of cellular oncogenes by DNA amplification is a frequent genetic alteration of cancer cells. In neuroblastoma, amplification of the gene MYCN has been associated with aggressively growing cancers and is an indicator for poor prognosis. MYCN amplification is of predictive value in identifying patients with neuroblastoma who require specific therapeutic regimens and those who do not benefit from chemotherapy.
通过DNA扩增增加细胞癌基因的剂量是癌细胞常见的基因改变。在神经母细胞瘤中，MYCN基因的扩增与侵袭性生长的癌症相关，是预后不良的一个指标。MYCN扩增在识别需要特定治疗方案的神经母细胞瘤患者以及那些无法从化疗中获益的患者方面具有预测价值。
